Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:49 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: T2DM (Type 2 Diabetes Mellitus)
Interventions: ORMD-0801, Placebo; Drug · Other
Lead sponsor: Oramed, Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 346 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Coral Gables, Florida

Conditions: Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions: AP-PA02, Placebo; Biological · Other
Lead sponsor: Armata Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 23
States / cities: Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more

Conditions: Obstructive Defecation Syndrome, Chronic Constipation, Rectocele, Intussusception
Interventions: Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler; Procedure
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: 21 Years to 80 Years · Female only
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 7
States / cities: Orlando, Florida • Burlington, Massachusetts • Minneapolis, Minnesota + 3 more

Conditions: Diabetes Mellitus Type 2
Interventions: GK Activator (2), Metformin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 259 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 22
States / cities: Chula Vista, California • Los Angeles, California • Spring Valley, California + 18 more

Conditions: Cancer
Interventions: forodesine hydrochloride; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Oral Mucositis
Interventions: ALD518, 0.9% saline; Biological · Drug
Lead sponsor: CSL Behring; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 13
States / cities: Clearwater, Florida • Boston, Massachusetts • Detroit, Michigan + 10 more

Conditions: Tuberous Sclerosis Complex
Interventions: everolimus; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 65 Years
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 14
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 11 more

Conditions: Diabetic Foot Ulcers
Interventions: Affinity Allograft, Standard of care; Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 8
States / cities: Miami Lakes, Florida • North Miami Beach, Florida • Clinton Township, Michigan + 5 more

Conditions: Non Small Cell Lung Carcinoma NSCLC
Interventions: Durvalumab +Tremelimumab, Paclitaxel + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + cisplatin, Pemetrexed + carboplatin; Biological · Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 953 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 15
States / cities: Anaheim, California • San Diego, California • Santa Rosa, California + 12 more

Conditions: Vaginal Infection
Interventions: Terconazole, Metronidazole, Terconazole/metronidazole; Drug
Lead sponsor: Curatek Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older · Female only
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 51
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 41 more

Conditions: Menopause
Interventions: esterified estrogens 1.25 mg and methyltestosterone 2.5 mg, Esterified estrogens 1.25 mg; Drug
Lead sponsor: Solvay Pharmaceuticals; Industry
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 78
States / cities: Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 75 more

Conditions: Spondylolisthesis
Interventions: Not listed
Lead sponsor: NuVasive; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 9
States / cities: Jacksonville, Florida • Kissimmee, Florida • Savannah, Georgia + 6 more

Conditions: Cancer, Pain
Interventions: Fentanyl sublingual spray; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 40
States / cities: Huntsville, Alabama • Winfield, Alabama • Glendale, Arizona + 37 more

Conditions: Systemic Lupus Erythematosus
Interventions: Placebo, Belimumab 1 mg/kg, Belimumab 10 mg/kg; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 819 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 67
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 56 more

Conditions: Hypertension, Diastolic Dysfunction
Interventions: valsartan, amlodipine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: USA, New Jersey

Conditions: Retinal Detachment
Interventions: denufosol tetrasodium (INS37217) Intravitreal Injection; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 33
States / cities: Tucson, Arizona • Beverly Hills, California • Los Angeles, California + 29 more

Conditions: Dry Eye Disease (DED)
Interventions: NOV03, Placebo; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 599 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 29
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Glendale, California + 25 more

Conditions: Pain
Interventions: OrthoCor Active System; Device
Lead sponsor: Caerus Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Gulf Breeze, Florida • Detroit, Michigan • Washington Township, New Jersey + 2 more

Conditions: Renal Cell Carcinoma
Interventions: ASONEP; Drug
Lead sponsor: Lpath, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Duarte, California • Fort Myers, Florida • Inverness, Florida + 2 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 14
States / cities: Phoenix, Arizona • Covina, California • Upland, California + 10 more

Conditions: Neuralgia, Spinal Cord Injuries
Interventions: placebo, pregabalin; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 22
States / cities: Phoenix, Arizona • Fresno, California • Napa, California + 15 more

Conditions: Head and Neck Cancer
Interventions: [F-18] FLT; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Orange, California

Conditions: Open Midline Laparotomy
Interventions: Phasix™ Mesh; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2031
U.S. locations: 20
States / cities: Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 17 more

Conditions: Demyelinating Disorders, Multiple Sclerosis, Optic Neuritis, Myelitis, Neuritis
Interventions: interferon beta 1a, methotrexate, methylprednisolone; Drug
Lead sponsor: MidAmerica Neuroscience Research Foundation at Rowe Neurology Institute; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 1
States / cities: Kansas City, Missouri

Search by objective public record fields.

A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)

A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.

BCX-1777 in Treating Patients With Refractory Cancer

Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects

Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment

Effect of Fresh Amniotic Membrane in the Treatment of Diabetic Foot Ulcers

Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)

Multi-Center Study of New Medications to Treat Vaginal Infections

The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women

XLIF® vs. MAS®TLIF for the Treatment of Symptomatic Lumbar Degenerative Spondylolisthesis With or Without Central Stenosis.

Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain

A Study of Belimumab in Subjects With Systemic Lupus Erythematosus

The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction

Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment

Perfluorohexylcotane (NOV03) for the Treatment of Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Gobi Study)

Study to Evaluate the OrthoCor Active System for Pain Relief

A Phase 2 Study of ASONEP™ to Treat Unresectable and Refractory Renal Cell Carcinoma

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury

Positron Emission Tomography Imaging With [F-18] FLT Compared to [F-18] FDG in Cancer Patients for Treatment Evaluation

Prophylactic Reinforcement of Ventral Abdominal Incisions Trial

Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.